Search hospitals > North Carolina > Huntersville
Carolina BioOncology Institute
Claim this profileHuntersville, North Carolina 28078
Global Leader in Solid Tumors
Global Leader in Tumors
Conducts research for Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Breast Cancer
94 reported clinical trials
2 medical researchers
Summary
Carolina BioOncology Institute is a medical facility located in Huntersville, North Carolina. This center is recognized for care of Solid Tumors, Tumors, Cancer, Non-Small Cell Lung Cancer, Breast Cancer and other specialties. Carolina BioOncology Institute is involved with conducting 94 clinical trials across 72 conditions. There are 2 research doctors associated with this hospital, such as John Powderly, M.D. and John D. Powderly II, MD.Area of expertise
1Solid Tumors
Global LeaderStage IV
Stage III
PD-L1 positive
2Tumors
Global LeaderStage IV
Stage III
ALK positive
Top PIs
John Powderly, M.D.Carolina BioOncology Institute2 years of reported clinical research
Expert in Solid Tumors
Expert in Tumors
39 reported clinical trials
68 drugs studied
John D. Powderly II, MDCarolina BioOncology Institute - Cancer Research Centre2 years of reported clinical research
Studies Solid Tumors
Studies Tumors
2 reported clinical trials
4 drugs studied
Clinical Trials running at Carolina BioOncology Institute
Solid Tumors
Tumors
Cancer
Prostate Cancer
Pancreatic Cancer
Colorectal Cancer
Breast Cancer
Non-Small Cell Lung Cancer
Ovarian Cancer
Squamous Cell Carcinoma
NUV-1511
for Solid Tumors
NUV-1511-01 is a first-in human, open- label, Phase 1/2 to evaluate the safety and efficacy of NUV-1511 in patients with advanced solid tumors. The Phase 1 portion include patients with advanced solid tumors and is designed to determine the safety and the tolerability of doses of NUV-1511. In Phase 2, NUV-1511 will be given to determine the efficacy of patients with advanced solid tumors.
Recruiting1 award Phase 1 & 2
AU-007
for Advanced Cancer
This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007 in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in combination with a single loading dose of aldesleukin, or with both AU-007 and aldesleukin given every 2 weeks (Q2w)
Recruiting1 award Phase 1 & 28 criteria
ABBV-303 + Budigalimab
for Solid Tumors
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-303 as a monotherapy and in combination with budigalimab, (ABBV-181). ABBV-303 is an investigational drug being developed for the treatment of solid tumors. There are multiple treatment arms in this study. Participants will either receive ABBV-303 as a single agent or in combination with budigalimab (another investigational drug) at different doses. Approximately 181 adult participants will be enrolled in the study across sites worldwide. In Part A, ABBV-303 will be intravenously (IV) infused in escalating doses as a monotherapy in participants with relapsed (R)/refractory (R) solid tumors, R/R non-small cell lung cancer (NSCLC), R/R renal cell carcinoma (RCC), R/R head and neck squamous cell carcinoma (HNSCC), or R/R tissue agnostic participants with mesenchymal epithelial transition. In Part B, ABBV-303 in combination with budigalimab will be IV infused in participants with R/R solid tumors or NSCLC. The estimated duration of the study is up to 3 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.
Recruiting1 award Phase 14 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Carolina BioOncology Institute?
Carolina BioOncology Institute is a medical facility located in Huntersville, North Carolina. This center is recognized for care of Solid Tumors, Tumors, Cancer, Non-Small Cell Lung Cancer, Breast Cancer and other specialties. Carolina BioOncology Institute is involved with conducting 94 clinical trials across 72 conditions. There are 2 research doctors associated with this hospital, such as John Powderly, M.D. and John D. Powderly II, MD.